期刊文献+

K-ras基因与乳腺癌复发的相关性分析 被引量:3

Analysis of relationship between K-ras gene mutation and breast cancer postoperative recurrence
原文传递
导出
摘要 目的观察K-ras基因突变与乳腺癌术后复发的关系。方法提取149个乳腺肿瘤组织样本(设为观察组),选取同一患者正常乳腺组织样本(设为对照组),用聚合酶链式反应-单链构象多态性分析和直接测序法对K-ras基因突变情况进行分析,并探讨K-ras突变与乳腺癌术后复发的相关性。结果乳腺癌组织中K-ras突变发生率(45.64%)明显高于正常乳腺组织(2.01%)(P<0.05)。K-ras突变患者的术后3年累计复发率为79.41%(45/68),明显高于未突变患者的25.92%(21/81)(P<0.05)。结论 K-ras突变可能是导致乳腺癌术后复发的原因之一,可作为临床预后判断指标。 Objective To investigate the relationship between K-ras gene mutation and the postoperative recurrence of breast cancer.Methods The 149 breast cancer tissue samples were extracted for the observation group, normal breast tissue samples of the same patients as control group. the K-ras gene mutation was analyzed by polymerase chain reaction single stranded conformation polymorphism (PCR-SSCP) and direct sequencing method. The correlation between K-ras mutation and the postoperative recurrence of breast cancer was investigated.Results Mutation rate of K-ras in breast cancer tissue (45.64%) was significantly higher than that in normal breast tissue (2.01%) (P〈0.05). Cumulative recurrence rate of K-ras mutation in patients with postoperative 3 year was 79.41% (45/68), significantly higher than that of patients without mutations(25.92%,21/81) (P〈0.05).Conclusion K-ras gene mutation is one of the reasons leading to a high postoperative recurrence in breast cancer patients. K-ras gene mutation can be used as a clinical prognostic indicator.
机构地区 浙江医院
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2014年第3期173-175,共3页 The Chinese Journal of Clinical Pharmacology
关键词 乳腺癌 术后复发 K-RAS 基因突变 breast cancer postoperative recurrence K-ras gene mutation
  • 相关文献

参考文献10

二级参考文献71

共引文献65

同被引文献41

  • 1Bourouba M, Benyelles-Boufennara A, Terki N, et al. Epidermal growth factor receptor(EGFR) abundance cor- relates with p53 and Bcl-2 accumulation and patient age in a small cohort of north african nasopharyngeal carcino- ma patients [ J ]. Eur Cytokine Netw, 2011,22 ( 1 ) : 38- 44.
  • 2Hwangbo W, Lee J H, Ahn S, et al. EGFR. Gene ampli- fication and protein expression in invasive ductal carcino- ma of the breast[ J ]. Korean J Pathol, 2013,47 (2) : 107- 115.
  • 3Corcoran R B, Conlino G, Deshpande V, et al. STAT3 plays a critical role in k-ras-induced pancreatic tumori- genesis [ J ]. Cancer Res, 2011,71 (14) :5020-5029.
  • 4Morris J P, Cano D A, Sekine S, et al. ~-catenin blocks k-ras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice[ J]. J Clin Invest, 2010, 120 ( 2 ) :508-520.
  • 5Watanabe T, Kobunai T, Yamamoto Y, et al. Gene ex-pression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients [J~. Clin Transl Oncol, 2011,13(6) :419425.
  • 6Hubert T, Vandekerckhove J, Gettemans J, et al. Cdkl and BRCA1 target ~-tubulin to microtubule domains[ J ]. Biochem Bio-phys Res Commun, 2011 , 414 ( 1 ) : 240- 245.
  • 7Wolff A C, Hammond M E, Hicks D G, et al. Recom- mendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical On- cology/College of American guideline update ~ ] ~. Arch (2) :241-256.
  • 8Pathologists clinical practice Pathol Lab Med, 2014,138 Ineorvati :l A, Shah S, Mu Y, et al. Targeted therapy for HER2 positive breast cancer [ J 1. J Hematol Oncol, 2013,6:38.
  • 9Dieras V, Bachelot T. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breastcancer[J]. Target Oncol, 2014,9(2) :111-122.
  • 10Ren J, Li G, Ge J, et al. Is K-ras gene mutation a prog- nostic factor for colorectal cancer: a systematic review and Rectum, 2012,55 (8) :913-.

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部